Preferential loss of expression of p16INK4a rather than p19ARF in breast cancer

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1993-1998

  Brenner, Andrew J ^a   Paladugu, Abhaya ^a   Wang, Hui ^a   Olopade, Olufunmilayo I ^b   Dreyling, Martin H ^b   Aldaz, C Marcelo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0030469779     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Olopade, O. I., Jenkins, R. B., Ransom, D. T., Malik, K., Pomykala, H., Nobori, T., Cowan, J. M., Rowley, J. D., and Diaz, M O. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res., 52: 2523-2529, 1992.
2. Heyman, M., Grander, D., Brondum-Nielsen, K., Liu, Y., Soderhall, S., and Einhorn, S. Deletions of the short arm of chromosome 9, including the interferon-α/-β genes, in acute lymphocytic leukemia. Studies on loss of heterozygosity, parental origin of deleted genes and prognosis. Int. J Cancer, 54: 748-753, 1993.
3. Center R., Lukeis, R., Dietzsch, E., Gillespie, M., and Garson, O. M. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes & Cancer, 7: 47-53, 1993.
4. Brenner, A. J., and Aldaz, C. M. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res., 55: 2892-2895, 1995.
5. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264, 436-440, 1994.
6. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
7. Merlo, A., Herman, J. G., Mao, L , Lee, D. J , Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
8. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
9. Herman, J G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J-P. J , Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
10. Dreyling, M. H., Bohlander, S. K., Adeyanju, M. O., and Olopade, O. I. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res., 55: 984-988, 1995.
11. Xiao, S., Li, D., Corson, J. M., Vijg, J., and Fletcher, J. A. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res., 55: 2968-2971, 1995.
12. Xiao, S., Li, D., Vijg, J., Sugarbaker, D. J., Corson, J. M., and Fletcher, J. A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 11: 511-515, 1995.
13. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
14. INK4A transcript. Cancer Res., 55: 2995-2997, 1995.
15. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
16. Bohlander, S. K., Espinosa, R., III, Fernald, A. A., Rowley, J. D., Le Beau, M. M., and Díaz, M. O. Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization. Cytogenet. Cell Genet., 65: 108-110, 1994.
17. Zhang, S-Y., Klein-Szanto, A. J. P., Sauter, E. R., Shafarenko, M., Mitsunaga, S., Nobori, T., Carson, D. A., Ridge, J. A., and Goodrow, T. L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54: 5050-5053, 1994.
18. Merlo, A., Gabrielson, E., Askin, F., and Sidransky, D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res., 54: 640-642, 1994.
19. Knowles, M. A., Elder, P. A., Williamson, M., Cairnes, J. P , Shaw, M. E., and Law, M. G. Allelotype of human bladder cancer. Cancer Res., 54: 531-538, 1994.
20. ink4) in human breast carcinomas. Cancer Res., 54: 5262-5264, 1994.
21. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E , Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaccs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours Nat. Genet., 11: 210-212, 1995.
22. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
23. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O., and Reznikoff, C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55: 493-497, 1995.